Acadia's Rett Syndrome Drug Daybue Wins Positive EU Opinion After Reexamination
ACAD sits 39% above its 52-week low of $19.69.
Summary
Acadia Pharmaceuticals' Rett syndrome drug, Daybue (trofinetide), received a positive opinion from the European Medicines Agency's CHMP after a reexamination, recommending marketing authorization in the EU. This is a significant reversal from the negative EU regulatory opinion for Daybue that was confirmed in the company's Q1 2026 10-Q filing on May 7th. The news is driving a 13% premarket surge in shares. This development materially expands the drug's potential market and revenue stream. The European Commission is expected to issue a final decision in the coming months.
At the time of this announcement, ACAD was trading at $27.32 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.1B. The 52-week trading range was $19.69 to $28.35. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Dow Jones Newswires.